Skip to search formSkip to main contentSkip to account menu

losoxantrone

Known as: 7-hydroxy-2(2-((2-hydroxyethyl) amino) ethyl)5-(2-((2-hydroxyethyl)amino)ethyl)amino anthra(1,9-cd)pyrazole-6(2H)-one 
An anthrapyrazole-based antineoplastic antibiotic. Losoxantrone intercalates into DNA, induces single- and double-stranded DNA breaks and inhibits… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
The oxidative biotransformation of the anticancer drug 7-hydroxy-2-[2-[(2-hydroxyethyl)amino]ethyl]-5-[[2-[(2-hydroxyethyl)amino… 
2001
2001
Losoxantrone is an anthrapyrazole derivative in Phase III development in the U.S. for solid tumors, notably breast cancer. To… 
2001
2001
The physicochemical and DNA-binding properties of anticancer 9-aza-anthrapyrazoles (9-aza-APs) were investigated and compared… 
2001
2001
Objectives: Systematic investigation of a novel series of intercalating agents, 9-aza-anthrapyrazoles, has led to the… 
2000
2000
Our purpose in this study was to determine the efficacy and toxicity of losoxantrone (DuP-941), an anthrapyrazole, in patients… 
1999
1999
A Phase I and pharmacological study was performed to evaluate the feasibility, maximum tolerated dose (MTD), dose-limiting… 
Review
1999
Review
1999
Numerous clinical trials have demonstrated that the combination of paclitaxel and doxorubicin is extremely active in metastatic… 
1996
1996
The validation of a procedure designed to clean glass and stainless steel surfaces after exposure to the experimental anticancer… 
Review
1994
Review
1994
The drug discovery programs of the National Cancer Institute and the pharmaceutical industry recently have provided oncologists…